ArticleLasers in medical science2025
Efficacy analysis of 450 nm semiconductor blue laser enucleation of the prostate in treating benign prostatic hyperplasia with urinary retention.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the clinical efficacy of 450 nm semiconductor blue laser enucleation of the prostate in patients with benign prostatic hyperplasia (BPH) complicated by acute urinary retention, and to assess its outcomes in patients with concomitant detrusor underactivity (DU).A retrospective analysis was conducted on clinical data from patients diagnosed with BPH and acute urinary retention who underwent 450 nm blue laser enucleation of the prostate in the Department of Urology at our hospital between February 2023 and May 2024. All patients had indwelling catheters due to acute urinary retention prior to surgery. Maximum urinary flow rate (Qmax), postvoid residual urine volume (PVR), International Prostate Symptom Score (IPSS), and quality of life (QoL) scores were compared before surgery and at 3 months postoperatively. Based on preoperative urodynamic testing, patients were divided into a DU group (bladder contractility index, BCI < 100) and a non-DU group (BCI ≥ 100). Surgical outcomes were compared between the two groups.A total of 62 patients were included in the study, with a mean age of 71.5 years. Of these, 32 (54.8%) were in the DU group and 28 (45.2%) in the non-DU group. At 3 months postoperatively, all patients showed significant improvements in Qmax, PVR, IPSS, and QoL scores compared with baseline (P < 0.001). In the DU group, 2 patients experienced recurrent urinary retention after catheter removal on postoperative day 3, but both recovered spontaneous urination after re-catheterization for 1 week. Intergroup comparisons showed that Qmax was lower and PVR was higher in the DU group than in the non-DU group at 3 months (P < 0.001), while no significant differences were observed in IPSS and QoL scores between the two groups (P > 0.05).The 450 nm semiconductor blue laser enucleation of the prostate is a safe and effective treatment for BPH complicated by acute urinary retention. Although patients with DU show less improvement in early postoperative voiding function compared to those without DU, the procedure effectively alleviates symptoms and may prevent further deterioration of detrusor function. These findings support its clinical application and wider adoption.
Indexed as
Identifiers
40976830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.